


Practitioner's Docket No. : MPI00-368P1RCN1M

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop Patent Application
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450



NEW APPLICATION TRANSMITTAL

Transmitted herewith for filing is the patent application of
Inventor(s): Maria A. Glucksmann, et al.

For: 57242, A NOVEL HUMAN G PROTEIN-COUPLED RECEPTOR FAMILY MEMBER AND
USES THEREFOR

1. Type of Application

This new application is for a(n)

- ☐ Original (nonprovisional)
- ☐ Design
- ☐ Plant
- ☐ Divisional.
- ☒ Continuation.
- ☐ Continuation-in-part (C-I-P).

CERTIFICATION UNDER 37 C.F.R. SECTIONS 1.8(a) and 1.10*

I hereby certify that, on the date shown below, this correspondence is being:

MAILING


- ☒ deposited with the United States Postal Service in an envelope addressed to the Mail Stop Patent Application,
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
37 C.F.R. SECTION 1.8(a)

37 C.F.R. SECTION 1.10*

- ☐ with sufficient postage as first class mail. ☒ as "Express Mail Post Office to Addressee"
Mailing Label No. EL992152636US

TRANSMISSION

- ☐ transmitted by facsimile to the Patent and Trademark Office.



Signature
Sean Hunziker

(type or print name of person certifying)

Date: September 18, 2003

***WARNING:** Each paper or fee filed by "Express Mail" must have the number of the "Express Mail" mailing label placed thereon prior to mailing. 37 C.F.R. Section 1.10(b).
"Since the filing of correspondence under [Section] 1.10 without the Express Mail mailing label thereon is an oversight that can be avoided by the exercise of reasonable care, requests for waiver of this requirement will not be granted on petition." Notice of Oct. 24, 1996, 60 Fed. Reg. 56,439, at 56,442.

Practitioner's Docket No. : MPI00-368P1RCN1M

2. Benefit of Prior U.S. Application(s) (35 U.S.C. Sections 119(e), 120, or 121)

- ☒ The new application being transmitted claims the benefit of prior U.S. Application Serial No. 09/942,374 filed August 29, 2001, which claims the benefit of prior U.S. Provisional Application Serial No. 60/228,409 filed August 29, 2000.

3. Maintenance of Copendency of Prior Application

- A. ☒ Extension of time in prior application filed concurrently by facsimile a copy of which is enclosed.
- B. ☐ Conditional Petition for Extension of Time in Prior Application
(complete this item, if previous item not applicable)
- ☐ A conditional petition for extension of time is being filed in the pending **prior** application.
- ☐ A copy of the conditional petition filed in the prior application is attached.

4. Abandonment of Prior Application (if applicable)

- ☐ Please abandon the prior application at a time while the prior application is pending, or when the petition for extension of time or to revive in that application is granted, and when this application is granted a filing date, so as to make this application copending with said prior application.

Notification in Parent Application of This Filing

- ☐ A notification of this continuation is being filed in the parent application from which this application claims priority under 35 U.S.C. Section 120.

5. Papers Enclosed

Required for Filing Date under 37 C.F.R. Section 1.53(b) (Regular) or 37 C.F.R. Section 1.153 (Design) Application

110 Pages of Specification, including
97 Pages of Description
12 Pages of Claims
1 Page of Abstract
0 Sheet of Drawings (Figure(s))

- ☐ The enclosed drawing(s) are photograph(s), and there is also attached a "PETITION TO ACCEPT PHOTOGRAPH(S) AS DRAWING(S)." 37 C.F.R. Section 1.84(b).
- ☐ Formal
- ☐ Informal

Practitioner's Docket No. : MPI00-368P1RCN1M

6. Additional Papers Enclosed

- ☒ Information Disclosure Statement (37 C.F.R. Section 1.98)(2 pages)
- ☒ Form PTO-1449 (PTO/SB/08A and 08B)(2 pages)
- ☐ Citations
- ☐ Declaration of Biological Deposit
- ☒ 4 pages of paper copy of Sequence Listing (37 CFR Section 1.821-1.823) and 4 pages of Submission of "Sequence Listing," Computer Readable Copy, and/or Amendment Pertaining Thereto for Biotechnology Invention Containing Nucleotide and/or Amino Acid Sequence (37 CFR Section 1.821(f))
- ☐ Authorization of Attorney(s) to Accept and Follow Instructions from Representative
- ☐ Special Comments
- ☒ Other: Copy of Petition for Extension of Time filed in prior U.S. Application Serial No. 09/942,374, filed August 29, 2001. (4 pages)
- ☒ Preliminary Amendment (6 pages)

7. Declaration or Oath (including power of attorney)

- ☒ (12 pages) Copy of the executed Declaration and Power of Attorney document filed in prior U.S. Application Serial No. 09/942,374, filed August 29, 2001.
- ☐ Not Enclosed.

8. Assignment

- ☒ (7 pages) Copy of the Assignment of the invention to Millennium Pharmaceuticals, Inc., filed in prior U.S. Application Serial No. 09/942,374, filed August 29, 2001, a copy of which
 - ☒ is enclosed.
 - ☐ will follow.

Practitioner's Docket No. : MPI00-368P1RCN1M

9. Fee Calculation (37 C.F.R. Section 1.16)

A. ☒ Regular application

CLAIMS AS FILED					
Claims	Number Filed	Basic Fee Allowance	Number Extra	Rate	Basic Fee 37 C.F.R. Section 1.16(a) \$750.00
Total Claims (37 C.F.R. Section 1.16(c))	29	- 20 =	9	\$18.00	\$162.00
Independent Claims (37 C.F.R. Section 1.16(b))	5	- 3 =	2	\$84.00	\$168.00
Multiple Dependent Claim(s), if any (37 C.F.R. Section 1.16(d))	0	\$280.00			\$0.00

Filing Fee Calculation

\$1080.00

- ☒ Amendment canceling extra claims is enclosed.
☐ Amendment deleting multiple-dependencies is enclosed.
☐ Fee for extra claims is not being paid at this time.

Practitioner's Docket No. : MPI00-368P1RCN1M

10. Method of Payment of Fees

- ☐ Check in the amount of \$_____.
- ☒ Charge Account No. 501668 in the amount of \$1080.00
- A duplicate of this transmittal is attached.

11. Authorization to Charge Additional Fees

- ☒ The Commissioner is hereby authorized to charge the following additional fees by this paper and during the entire pendency of this application to Account No. 501668.
- ☒ 37 C.F.R. Section 1.16(a), (f) or (g) (filing fees)
- ☒ 37 C.F.R. Section 1.16(b), (c) and (d) (presentation of extra claims)
- ☐ 37 C.F.R. Section 1.16(e) (surcharge for filing the basic filing fee and/or declaration on a date later than the filing date of the application)
- ☒ 37 C.F.R. Section 1.17(a)(1)-(5) (extension fees pursuant to Section 1.136(a).
- ☒ 37 C.F.R. Section 1.17 (application processing fees)
- ☐ 37 C.F.R. Section 1.18 (issue fee at or before mailing of Notice of Allowance, pursuant to 37 C.F.R. Section 1.311(b))

12. Instructions as to Overpayment

- ☒ Credit Account No. 501668.
- ☐ Refund

13. Correspondence Address

Direct all future correspondence to:

Customer Number 30405
OR
Intellectual Property Department
MILLENNIUM PHARMACEUTICALS, INC.
75 Sidney Street
Cambridge, MA 02139

September 18, 2003

MILLENNIUM PHARMACEUTICALS, INC.

By Kerri Pollard Schray
Kerri Pollard Schray
Registration No. 47,066
75 Sidney Street
Cambridge, MA 02139
Telephone – (617) 551-3676
Facsimile – (617) 551-8820

☒ Statement Where No Further Pages Added

- ☒ This transmittal ends with this page.

TO:Auto-reply fax to 617 551 8820 COMPANY:

COPY

Auto-Reply Facsimile Transmission



UNITED STATES
PATENT AND
TRADEMARK OFFICE

TO:

Fax Sender at 617 551 8820

Fax Information

Date Received:

Total Pages:

9/18/03 10:41:43 AM [Eastern Daylight Time]

5 (including cover page)

ADVISORY: This is an automatically generated return receipt confirmation of the facsimile transmission received by the Office. Please check to make sure that the number of pages listed as received in Total Pages above matches what was intended to be sent. Applicants are advised to retain this receipt in the unlikely event that proof of this facsimile transmission is necessary. Applicants are also advised to use the certificate of facsimile transmission procedures set forth in 37 CFR 1.8(a) and (b), 37 CFR 1.6(f). Trademark Applicants, also see the Trademark Manual of Examining Procedure (TMEP) section 306 et seq.

Received
Cover
Page

=====>

09/18/03 10:41:43 FAX 617 551 8820		RECEIVED		001	
<p><small>Burden Hour Statement: This form is estimated to take 0.03 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.</small></p>					
<p>Practitioner's Docket No. MPI00-36KPIRM (703) 872-9306</p>			<p>PATENT</p>		
<p>Certificate of Transmission under 37 CFR 1.8</p>					
<p>I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office On September 18, 2003</p>					
<p><u>Diana Gentile</u> Signature</p>					
<p>Diana Gentile Typed or printed name of person signing Certificate</p>					
<p>Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.</p>					
<p>Submitted herewith:</p>					
<p>Transmittal with Request for Extension of Time</p>			<p>2 pages—in duplicate</p>		
<p>Total</p>			<p>5 pages (including cover)</p>		
<p><small>USPS 007 (08-00) Approved for use through 10/31/2002. OMB 0051-0021 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</small></p>					
<p>Received from - 617 551 8820 - at 9/18/03 10:41:43 AM [Eastern Daylight Time]</p>					

Practitioner's Docket No. MPI00-368P1RM
(703) 872-9306

PATENT

Certificate of Transmission under 37 CFR 1.8

I hereby certify that this correspondence is being facsimile transmitted to the
United States Patent and Trademark Office

On September 18, 2003


Signature

Diana Gentile

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of transmission, or this certificate must identify each submitted paper.

Submitted herewith:

Transmittal with Request for Extension of Time

2 pages—in duplicate

Total

5 pages (including cover)

TO/SB/97 (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.